Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,979 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02844647 | Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer | terminated | Phase 1 | 2 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03440879 | Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose | terminated | N/A | 23 | Norwegian School of Sport SciencesOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT04423913 |
| Safety, Tolerability, Distribution & Dose Effect of Neoadjuvant Transarterial Chemoembolization With Doxorubicin in Prostate Cancer Patients Before Radical Prostatectomy(CAPEMCHAR) |
| terminated |
| Phase 2 |
| 12 |
| Centre Hospitalier Universitaire de NīmesOTHER |
| 1 |
| Mar 27, 2023 |
| clinicaltrials |
| NCT01709734 | A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer(ARMOR2) | terminated | Phase 2 | 126 | LTN PHARMACEUTICALS, INC.INDUSTRY | 2 | Mar 15, 2023 | clinicaltrials |
| NCT02438007 | A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC(ARMOR3-SV) | terminated | Phase 3 | 953 | LTN PHARMACEUTICALS, INC.INDUSTRY | 8 | Mar 15, 2023 | clinicaltrials |
| NCT03439033 | Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer | terminated | Phase 2 | 273 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT03921996 | Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer | terminated | Phase 3 | 57 | Swiss Cancer InstituteOTHER | 1 | Mar 9, 2023 | clinicaltrials |
| NCT05744115 | Ga-68-PSMA-11 in Men With Prostate Cancer(Ga68-PSMA-11) | terminated | Phase 3 | 38 | Timothy HoffmanFED | 1 | Feb 24, 2023 | clinicaltrials |
| NCT04873427 | In Situ Clonal Heterogeneity in Prostatic Diagnostic Biopsies | terminated | — | 40 | Clinica Luganese MoncuccoOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT02721979 | Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance | terminated | Phase 2 | 24 | University of WashingtonOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT02420652 | Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy(PRIMA) | terminated | Phase 2 | 27 | Rutgers, The State University of New JerseyOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT01045226 | Proton Radiation Therapy in Treating Patients With Prostate Cancer | terminated | N/A | 300 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT02146833 | SHIP (Selinexor in Hormone Insensitive Prostate Cancer)(SHIP) | terminated | Phase 2 | 20 | Karyopharm Therapeutics IncINDUSTRY | 1 | Jan 26, 2023 | clinicaltrials |
| NCT03796195 | (SGB) in Men Treated for Prostate Cancer Improve Hot Flashes | terminated | Phase 4 | 1 | Northwestern UniversityOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT03111914 | Applications of Dual Energy CT in Patients With Osseous Metastases From Castrate-resistant Prostate Cancer | terminated | N/A | 7 | Duke UniversityOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT04457245 | Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer(PSMA-dRT) | terminated | Phase 3 | 54 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT03365076 | Exercise for Improving Prostate Oxygenation in Prostate Tumors (Exipox)(EXIPOX) | terminated | N/A | 1 | University Hospital of North NorwayOTHER | 1 | Jan 9, 2023 | clinicaltrials |
| NCT02454517 | Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer(PALS) | terminated | N/A | 117 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT02745587 | Evaluating the Impact of Prostate Only Versus Pelvic Radiation for N+ Prostate Cancer.(PROPER) | terminated | Phase 3 | 69 | University Hospital, GhentOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT03971110 | A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy. | terminated | Phase 4 | 9 | AstraZenecaINDUSTRY | 1 | Dec 16, 2022 | clinicaltrials |
| NCT04928820 | 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy | terminated | Phase 2 | 22 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT04727710 | Testing the Effect of Mindfulness for Prostatectomy Outcomes(TEMPO) | terminated | N/A | 1 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT04237584 | A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients(ESCALATE) | terminated | Phase 3 | 23 | MANA RBMOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT01174199 | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 1 | 13 | Roswell Park Cancer InstituteOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT04535908 | Hypofractionated Radiotherapy in Prostate Cancer Patients Aged 75 Years or Older. | terminated | N/A | 23 | Medical University of GrazOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT02766478 | Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer(GeniPro) | terminated | Phase 2 | 10 | Emory UniversityOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT04279561 | Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer | terminated | Phase 1 | 9 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT02203513 | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer | terminated | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT02419846 | Informed Decision Making Intervention in Screening for Prostate Cancer of Predominantly African American Participants in a Community Outreach Program | terminated | N/A | 319 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT03531827 | Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Jul 12, 2022 | clinicaltrials |
| NCT01681433 | OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone | terminated | Phase 2 | 72 | Costantine AlbanyOTHER | 2 | Jul 11, 2022 | clinicaltrials |
| NCT02582749 | Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases | terminated | Phase 2 | 16 | Ajjai Alva, MDOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT04634344 | Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC | terminated | Phase 1 | 16 | Dizal PharmaceuticalsINDUSTRY | 2 | Jul 11, 2022 | clinicaltrials |
| NCT02663908 | A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease(PRONOUNCE) | terminated | Phase 3 | 545 | Ferring PharmaceuticalsINDUSTRY | 12 | Jun 29, 2022 | clinicaltrials |
| NCT03964337 | Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer(SPARC) | terminated | Phase 2 | 3 | Duke UniversityOTHER | 1 | Jun 29, 2022 | clinicaltrials |
| NCT03290508 | Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer | terminated | — | 524 | Myriad Genetic Laboratories, Inc.INDUSTRY | 1 | Jun 23, 2022 | clinicaltrials |
| NCT02365883 | Transrectal Photoacoustic Imaging of the Prostate | terminated | — | 22 | Stanford UniversityOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT03152448 | Prospective Prolaris Value and Efficacy(P-PROVE) | terminated | — | 1,511 | Myriad Genetic Laboratories, Inc.INDUSTRY | 1 | Jun 13, 2022 | clinicaltrials |
| NCT03367819 | Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 44 | SanofiINDUSTRY | 5 | May 16, 2022 | clinicaltrials |
| NCT02913131 | Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies | terminated | Phase 1 / Phase 2 | 23 | Rahul AggarwalOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT02945813 | SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy | terminated | Phase 2 | 112 | Swiss Cancer InstituteOTHER | 3 | Apr 14, 2022 | clinicaltrials |
| NCT02349386 | Maintaining Suppression of Testosterone With Transdermal Estradiol Gel(MASTERS) | terminated | Phase 2 | 34 | BHR Pharma, LLCINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04357717 | ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting | terminated | — | 150 | Exosome Diagnostics, Inc.INDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04221828 | Trial of NanoPac Focal Therapy for Prostate Cancer | terminated | Phase 2 | 1 | NanOlogy, LLCINDUSTRY | 1 | Mar 29, 2022 | clinicaltrials |
| NCT03366792 | Comparative Analysis of Transperineal Versus Transrectal Approaches for MRI-Targeted Biopsy of the Prostate for the Detection and Characterization of Prostate Cancer | terminated | N/A | 46 | NYU Langone HealthOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT02362451 | Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer | terminated | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Mar 18, 2022 | clinicaltrials |
| NCT04960956 | Glycosylation of Exosomes in Prostate and Urothelial Carcinoma | terminated | — | 13 | Indiana UniversityOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT04393831 | A Prospective Trial on Nerve Sparing Techniques Performed in Radical Prostatectomy | terminated | N/A | 3 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT01650285 | Cabazitaxel and Radiation For Patients With Prostate Cancer | terminated | Phase 2 | 5 | Brown UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Mar 28, 2023source: clinicaltrials